TNF and rheumatoid arthritis: The advent of biological disease-modifying anti-rheumatic drugs (bDMARDs), such as tumor necrosis factor-α (TNF-α) inhibitors, interleukin-6 receptor blockers, and B cell depletion agents, which are differentiated from cDMARDs, has been a breakthrough in the treatment of RA.